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Purpose: To give a better understanding of primary AE, the clinical characteristics and the
possible therapeutic approaches.
Background: Angioedema (AE) is a non-pitting, non-itching swelling of skin or mucosa.
The symptom can become life-threatening if located in the airways. Primary (monosympto-
matic) AE is a manifestation of several different diseases and the diagnosis is not always
straight-forward. The aetiological and pathophysiological factors of primary AE are not
completely clarified. There is a need for further investigation.
Patients and Methods: This was a retrospective cohort study of patients referred to an
outpatient dermatology clinic in a tertiary care hospital for clinical assessment due to primary
AE in the period from 1996 to 2014.
Results: A total of 315 patients were identified with primary AE. The most frequent subtype
was idiopathic AE (42.5%) and the second most common was angiotensin-converting
enzymeinhibitor (ACEi)-induced AE (31.1%). Three patients were diagnosed with hereditary
AE and one patient was diagnosed with acquired C1-inhibitor deficiency. At least 107
(34.0%) patients had established histaminergic AE. More than 1/3 of the patients were
treated in an emergency room or hospitalized due to AE. A 98.1% of patients had experi-
enced AE in the head and neck area. Seven patients were in the need of acute airway
intervention. Six of these had ACEi-induced AE. Female sex and smoking were found to be
risk factors for developing AE.
Conclusion: The most frequent diagnoses were histaminergic-, non-histaminergic idiopathic
AE and ACEi-induced AE, whereas complement C1-inhibitor deficiency was rare.
Histaminergic AE made up a substantial group of patients with primary AE. Even though
there are different pathophysiological causes of AE, many cases have overlapping clinical
manifestations, which make diagnosis and treatment difficult.
Keywords: primary angioedema, urticaria, hereditary angioedema, angiotensin-converting
enzyme inhibitors, bradykinin
Background
Angioedema (AE) is a non-pitting, self-limiting swelling of skin and mucosa, which
can become life-threatening when located in the airways. The condition is caused by an
increase in vascular permeability due to different mediators.1 More than one-third of
AE cases are estimated to be associated with urticaria.2,3 AE and urticaria can be seen
as different manifestations of common pathological processes. AE is located to the
deeper layer of the skin and the maximum duration of the symptom is 7 days, whereas
urticaria is located in the superficial dermis with a duration of 1–24 hours.4,5
AE can be defined as either acquired (AAE) or hereditary (HAE). AAE can be
further sub-divided into several categories: idiopathic histaminergic AE, idiopathic
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non-histaminergic AE, ACEi-induced AE and acquired
complement C1-inhibitor deficiency (C1-INH-AAE). An
AAE subgroup associated with allergic reactions has been
described by some studies.1,6 HAE is categorized into
HAE with C1-INH deficiency (C1-INH-HAE) and HAE
with normal C1-INH.7 The former is associated with muta-
tions in the SERPING1 gene whilst the latter has been
associated with mutations of the following genes: Factor
XII, angiopoietin-1, plasminogen and kininogen 1.8,11
C1-INH-HAE is an autosomal dominant hereditary
disease with a prevalence of 1:50.000–1:71.000.12,13 C1-
INH-AAE has an even lower prevalence estimated as 1:10
of C1-INH-HAE patients.14,15 Histaminergic AE is caused
by a release of histamine from mast cells and basophils
and often presents with concomitant urticaria.1 Non-
histaminergic AE is associated with bradykinin and sub-
stance P release from the contact system and sensory nerve
endings.16 Bradykinin-mediated AE is not associated with
urticaria and does not respond to anti-allergic therapy with
antihistamines, corticosteroids or adrenaline.1 Even though
there are different pathophysiological causes of AE, many
cases have overlapping clinical manifestations, which
makes diagnosis and treatment difficult.17,18 Overall the
treatment of AE depends on the symptoms. AE attacks are
self-limiting and last 1–7 days without medical treatment.
Recurrent AE attacks are associated with a significant
reduction in health-related quality of life due to limitations
in daily activity, fear of suffocation and in some cases
worries about heritability.19
The current treatment of acute AE in patients who have
not been diagnosed with C1-INH deficiency consists of
corticosteroids, antihistamines and in severe cases adrenalin.
Histamine is the predominant cause of AE and the current
acute first line of treatment thus favours patients with hista-
minergic AE.20 Patients with swelling attacks due to C1-
INH deficiency can effectively be treated with C1-INH
concentrate or a bradykinin receptor antagonist.21,23
The objective of this study is to describe the clinical
characteristics of patients found to have primary AE in
order to give a better understanding of the disease.
Patients and Methods
Study Population
This was a retrospective observational cohort study of
patients with primary AE. Seven hundred and thirty-four
patients were referred to a dermatology department in
a tertiary care hospital due to a suspicion of AE between
01-01-1996 and 31-12-2014. Patients were included if they
had experienced AE at least once. The patients were
selected based on International Classification of Diseases
Version 10 (ICD-10) diagnostic codes possibly linked to
the AE diagnosis: DT78.3 Quincke’s edema, DL50
Urticaria, or DD84.1A Hereditary angioedema. One hun-
dred and thirty-two patients were excluded due to insuffi-
cient clinical information. Seventy-four patients were
excluded due to missing concluding AE diagnosis by
a dermatologist (defined as DT78.3 Quincke’s edema or
DD84.1A Hereditary angioedema). Four patients were
excluded due to other underlying factors of swellings
such as Melkersson–Rosenthal syndrome or Panniculitis.
Two hundred and nine patients were excluded due to
concomitant urticaria (DL50.8A Chronic urticaria,
DL50.8B Urticaria recidivans, DL50.8D Urticaria acuta,
DL50.8E Urticaria due to pressure, DL50.1 Idiopathic
urticaria, DL50.8 Other forms of urticaria). A total of
315 patients were diagnosed with primary AE (Figure 1).
Data Extraction
Baseline characteristics such as sex, age, underlying cause
of AE, ICD-10 codes, anatomical site of AE, daily drug
intake, comorbidities, treatment, hospitalization and fol-
low-up time were obtained from patient medical records
in an electronic data system. The follow up time was
calculated from the first visit to ended clinical investiga-
tion by a dermatologist.
Data Sources
The drug sales information for the Danish background
population was acquired from the Register of Medicinal
Product Statistics (Medstat.dk) for comparative statistical
analysis.24 This registry dates back to 1999; hence, data
from the background population was only to be found
from 1999 to 2014. Eight patients in the cohort were
referred before 1999 and were excluded in the analysis
of daily drug intake only. Drug intake information for the
patients was obtained for 308 patients. Comorbidity in the
background population was extracted from Sundhed og
Sygelighed 2010 and hjertesvigt.dk.25,26
Diagnosis
Idiopathic AE was used as a diagnosis of exclusion by
a dermatologist when no specific underlying factors of AE
attacks were identified after clinical and biochemical
assessment. Patients were diagnosed with idiopathic hista-
minergic AE if symptoms resolved following the
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continuous administration of antihistamines. Patients were
diagnosed with idiopathic non-histaminergic AE diagnosis
if symptoms did not resolve following continuous admin-
istration of high dose antihistamines. Patients were diag-
nosed with allergic AE if symptoms clearly occurred after
allergen exposure and they had a positive skin prick test
and/or positive histamine-release test of allergen-specific
IgE. In other cases, a specific causative factor was identi-
fied, as the AE stopped after the elimination of a specific
drug or underlying infection.
Patients were diagnosed with ACEi-induced AE if they
received ACEi during an AE attack and no other cause of
AE was found. Patients were diagnosed with NSAID-
induced AE if symptoms started after NSAID intake and
improved after drug discontinuation. HAE and C1-INH-
AAE were diagnosed according to established criteria.7
Statistical Analysis
Analyses and calculations were performed in SPSS-24.
A calculation of frequencies between the AE group and the
Figure 1 Patients with primary AE included in study. Seven hundred thirty-four patients referred to a dermatology department. Three hundred fifteen patients included in
study.
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general population was performed using the binomial distri-
bution. Multivariate logistic regression was used to calculate
the risk of admission due to different factors. p values ≤ 0.05
were considered statistically significant.
Ethics
This study was approved by the Danish Data Protection
Agency (jr. number 14/35206) and the Danish National
Board of Health (jr. number 3–3013-805/1/) as appropriate.
Results
Of 734 referred patients 315 were found to have primary
AE (Figure 1). There were significantly more females
(59.0%) compared to males (p=0.001). The mean age at
referral was 52.1 years. At AE onset the mean age was
48.2 years. The cohort mostly consisted of Caucasians
(97.5%). Data regarding smoking was available in 199
patients and 64 (32.2%) were current smokers. Our study
found significantly more current smokers amongst primary
AE patients compared to the background population in
a binomial distribution (p<0.001) (Table 1).
Idiopathic AE was most frequent (42.5%). Eighty-two
of 134 patients continued using antihistamines and could
be classified as histaminergic or non-histaminergic AE.
Among these patients, 59 (72%) were idiopathic histami-
nergic AE and 23 (28%) were idiopathic non-
histaminergic AE. For 52 patients the data was insufficient
since the use of long-term antihistamines was not expli-
citly noted, or the follow-up time was too short to evaluate
treatment response. Histaminergic AE was established in
at least 107 (34.0%) cases (idiopathic histaminergic AE
and AE associated with an allergic reaction). The second
most frequent cause of primary AE was ACEi usage.
A total of 10 patients experienced AE as a result of
NSAID usage (Figure 2). Nineteen patients (6.0%) had
AE due to a drug response associated with an allergic
reaction caused by a drug that was not NSAID and ACEi
(Figure 2). The drugs were penicillin,1 calcium-
antagonists,3 female hormonal therapy,2 simvastatin,2 ser-
otonin reuptake inhibitor,2 metformin,1 allopurinol,1
donepezil,1 metoprolol,1 fluconazole,1 and mefloquine.1
The rest of the patients experienced remission when sev-
eral medications were discontinued, but the exact drug was
not confirmed.3 Drug-related AE developed in 40.3% of
the cases (NSAID, ACEi and drug response associated
with an allergic reaction). For patients with infection-
related AE, the infections were tooth infection, otitis,
herpes zoster, helicobacter pylori, tuberculosis, and mono-
nucleosis. AE was also seen together with the autoimmune
disease cutaneous lupus erythematosus and cancer-related
with T-cell lymphoma. The other underlying factors of AE
are displayed in Figure 2.
The medical treatment of AE was mainly anti-allergic
(antihistamines, corticosteroids and adrenaline). However,
24 (7.6%) patients were treated with other drugs for their
AE attacks. Six patients were treated with tranexamic acid,
six patients received a bradykinin receptor antagonist, and
two patients were treated with C1-INH concentrate
(Table 2).
Hospitalizations, as a result of AE, were reported in
136 (43.2%) patients. The days of hospitalization ranged
between 1 and 35 with a mean number of 3.2 days. One
hundred and twenty-seven patients (40.3%) had been
referred to the ER with a mean number of visits of 1.9.
Seven patients needed acute airway management due to
swelling of the airways. Four of them females, three
males, a mean age at onset 72 years. Six of them had
ACEi-induced AE, and one was AE associated with an
allergic reaction. Four females and three males (Table 3).
Table 1 Basic Data of 315 Patients with Primary Angioedema in
the Cohort
Patients, n 315
Male; Female ratio 129;186
Period of referral 01-05-1996; 31-12-2014
Frequent smoker of 199 patients n (%) 64 (32.2)
Ethnicity 307 caucasian,1 Black, 4
Asian, 3 unknown/others
95% CI Range
Age at referral, years 52.1 50.2–54.0 3–91
Age at onset, years 48.2 46.1–50.2 0–86
Family history of AE or urticaria n (%) Yes 36 (11.4)
No 247 (78.4)
Unknown 32 (10.2)
Localization of AE Located in n (%)
AE in head and neck area 309 (98.1)
Intra-abdominal AE 11 (3.5)
Peripheral AE 62 (19.7)
Multifocal AE 64 (20.3)
Abbreviations: CI, confidence interval; AE, angioedema.
Pall et al Dovepress
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A parameter significantly associated with hospitalization
was older age at referral. The odds ratio (OR) of hospita-
lization increased 3.0% for every year a patient increased
in age. Comorbidities significantly associated with hospi-
talization were diabetes, hypertension, ischaemic heart
disease, heart failure, allergy and asthma. Patients with
ACEi-induced AE had a statistically significant greater
risk of being admitted, whereas idiopathic AE patients
had a statistically significant lower risk of being admitted
(Table 4). The most frequent anatomical site of AE was the
head and neck area (98.1%) whereas abdominal AE was
the least frequent site of AE (3.5%). Patients with abdom-
inal AE always manifested with AE in other locations as
well. Sixty-two (19.7%) patients had experienced periph-
eral AE. One-fifth (20.9%) were reported with multifocal
AE (Table 1).
General practitioners (47.6%), internists (20.0%), otor-
hinolaryngologists (10.5%), and dermatologists (9.8%)
were the physicians who most often referred the patients
to the dermatology department.
A 12.8% of patients did not have their follow-up time
registered. A 9.1% of patients did not require any follow-
up (follow-up = 0 days). A 72.5% of patients had one
follow-up appointment in the out-patient department with
a mean follow-up period of 139.1 days. A 5.9% attended
the out-patient department at least twice with a mean
follow up of 215 days. The mean follow-up time for all
referrals was 146.7 days (95% CI 128.4–170.2). The mini-
mum follow-up time was 1 day, and the maximum follow-
up time was 1415 days, ie, almost 4 years.
Five comorbidities were significantly more prevalent in
the cohort compared to the background population: dia-
betes, hypertension, ischemic heart disease, heart failure
and allergy. Allergy was the only significant prevalent
comorbidity in the cohort group when patients with ACEi-
induced AE were not a part of the calculation. Drug intake
and comorbidities in the cohort and comparison to the
background population are shown in Table 5.
Discussion
In this study of 315 primary AE patients referred to
a outpatient clinic in a tertiary care hospital, we found idio-
pathic histaminergic and non-histaminergic AE and ACEi-
induced AE to be the most frequent underlying factors of
AE in a tertiary referral centre. Most of the idiopathic cases
(72%) responded to antihistamines. The use of continuous
antihistamines was not noted in the journals of 52 patients;
hence, the number of histaminergic AE patients in the study
population may be higher than noted. Thirty-four percent of
patients were diagnosed with histaminergic AE, illustrating
Figure 2 Underlying factors in 315 primary AE patients.
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that histaminergic AE can also present without hives. Twenty-
one (6.7%) patients developed AE related to specific external
agents or concomitant diseases such as autoimmune diseases,
cancer, infection, physical stimuli or Hypereosinophilic syn-
drome. This supports prior findings of how non-allergic
external agents or concomitant diseases do sometimes man-
ifest with primary AE.4 Only three patients were diagnosed
with HAE and one patient with C1-INH-AAE. This supports
the consensus of C1-INH-AAE and -HAE as very rare under-
lying factors of primary AE.7,27 ACEi-induced AE was seen
Table 2 Treatment of AE, Standard Therapy Treatment (Antihistamine, Corticosteroids and if Necessary Adrenaline/Epinephrine) and
Second Line Drug Treatment of AE Incidents
Acute Medical Treatment Yes, n (%) No, n (%) Unknown, n (%)
Antihistamine 287 (91.3) 19 (6.0) 9 (2.9)
Antihistamine efficacy 184 (64.1) 36 (12.5) 67 (23.3)
Corticosteroid 199 (63.2) 109 (34.6) 6 (1.9)
Corticosteroid efficacy 123 (61.8) 17 (8.5) 59 (29.6)
Adrenalin 52 (16.5) 256 (81.3) 7 (2.2)
Adrenalin efficacy 21 (40.4) 7 (13.5) 24 (46.2)
No standard drug administered (antihistamine, corticosteroids, adrenalin) 17 (5.4) 289 (91.7) 9 (2.9)
Second line drug treatment of AE 24 (7.4) Triggering factor related to second line
treatment of AE
Bradykinin receptor antagonist (icatibant) 6 Five with ACEi-AE and one with idiopathic AE
Tranexamic acid 6 Two with AE due to physical stimuli, two patients with
idiopathic AE, one ACEi AE and one HAE patient
Leukotriene D-4 receptor antagonist 5 Four with idiopathic AE, one with allergy
Azathioprine 3 All idiopathic AE
Glucocorticoids (inhalation) 2 Two with infection
C1-INH concentrate 2 One HAE and one with AE due to physical stimuli
Attenuated androgens (danazol) 2 One with AE due to physical stimuli and one with
idiopathic AE
Beta-2 agonist 2 Both ACEi AE, one of these with asthma
Topical corticosteroid 1 Drug-induced AE
Antibiotics 1 One patient with infection
Abbreviations: AE, angioedema; n, number of patients.
Table 3 Data Regarding ER Visits and Hospitalization
Yes, n (%) No, n (%) Unknown, n (%)
Number of patients hospitalized 136 (43.2) 179 (56.8)
Airway management 7 (2.2) 178 (55.6) 135 (42.2)
Number of patients Mean number CI Range
Duration of admission, days 129 3.2 2.4–3.9 1–35
Number of visits at ER 127 1.9 1.6–2.1 1–9
Abbreviations: ER, emergency room; n, number of patients; CI, 95% confidence interval.
Pall et al Dovepress
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in almost one-third of the cohort. Recent studies suggest an
increase in ACEi-induced AE as a result of an increase in
ACEi prescriptions.28 ACEi-induced AE was first reported in
1984 and 0.1–2.2% of all ACEi users are estimated to develop
AE.29,31
Ten patients (3.2%) had AE due to NSAIDs. It has
been hypothesized that NSAID-induced AE is not an
allergic reaction per se, but is due to excessive leukotriene
production as a result of COX1 blocking.6,32 Eighteen
(5.6%) patients developed AE due to the use of another
drug and were categorized as allergic.
Leeyaphan et al described NSAIDs and penicillin as
drugs frequently associated with drug-induced AE.33,34
Calcium-antagonists, statins, metformin, metoprolol,
female hormones, has also been reported in prior cases
and are estimated as less frequent inducers of AE.33,35,38
This study confirms existing evidence in the area, that non-
ACEi drug-induced AE does sometimes occur without
concomitant hives.
The use of NSAIDs and female hormones in the back-
ground population was more frequent than seen in our
study population. The underuse of female hormones is
likely due to the higher mean age of the cohort group
compared to the background population so especially
birth control pills are less used in our cohort. Also, patients
with AE are sometimes discouraged to use estrogens and
often discouraged to use NSAIDs.
Our study found female sex to be a risk factor of
primary AE. These results support prior findings of female
predominance in AE patients.4,39 Five hundred and
twenty-four patients with AE were identified, but 39.9%
presented with concomitant urticaria. The primary AE: AE
with concomitant urticaria-ratio was 1.5, a ratio adjacent to
1.4 found by Mansi et al and 1.7 by Madsen et al.2,40 This
study supports how histaminergic AE does not always
manifest with urticaria, which makes it is difficult to
differentiate between histaminergic and non-histaminergic
AE based on clinical appearance. Why some histamine
related AE patients present with urticaria and some do
not are unknown. Eli et al have hypothesized how
a greater activation of contact pathways and bradykinin
production in primary AE leads to vasodilation of the
deeper dermal layers, compared to AE patients with con-
comitant urticaria.41
Most AE attacks were located in the head and neck area
(98.1%), these findings support other studies.4,40,42 Only
seven patients were in the need of acute airway management.
However, this should be taken seriously due to the high risk
of asphyxiation. Six of these were ACEi-induced AE. This
states a greater risk of airway intervention in ACEi-induced
Table 4 Association Between Different Variables and the Need for Admission
OR SE CI p value
Female sex 0.677 0.231 0.430–1.065 0.092
Current smoker 1.295 0.304 0.714–2.351 0.395
Family history of AE/urticaria 1.837 0.360 0.908–3.718 0.091
Age at referral 1.030 0.007 1.015–1.044 <0.001 *
Diabetes 2.591 0.368 1.259–5.329 0.010*
Hypertension 2.110 0.234 1.334–3.337 0.001 *
Ischemic heart disease 3.487 0.465 1.402–8.674 0.007 *
Heart failure 4.113 0.677 1.091–15.504 0.037*
Asthma 3.104 0.403 1.409–6.838 0.005 *
Known allergy 1.843 0.251 1.127–3.017 0.015*
Atopic dermatitis 0.908 0.507 0.336–2.451 0.849
Allergic rhinitis 1.049 0.357 0.521–2.110 0.894
ACEi-induced AE 1.959 0.247 1.207–3.180 0.006*
Idiopathic-induced AE 0.534 0.234 0.337–0.845 0.007*
Notes: *Statistically significant result in relation to OR of admission. Multivariate logistic regression analysis.
Abbreviations: OR, odds ratio; SE, standard error; CI, 95% confidence interval.
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Table 5 Comorbidity and Daily Drug Intake in the Cohort Compared to the Background Population
Daily Drug Intake Yes, n (%) No, n (%) Background Population % p-value, Binomial Test
Antihypertensive drugs 132 (42.9) 176 (57.1)
ARB 7 (2.3) 301 (97.7) 3.80 0.099
ACEi 98 (31.8) 210 (68.2) 5.64 <0.001*
Systemic corticosteroids 8 (2.6) 300 (97.4) 3.27 0.321
Diabetic drugs 28 (9.0) 280 (90.9) 2.90 <0.001*
NSAID (prescribed) 25 (8.1) 283 (91.9) 15.3 <0.001*
Antihistamines 44 (14.3) 264 (85.7) 4.90 <0.001*
Thrombocyte inhibitors 54 (18.0) 254 (82.0) 8.00 <0.001*
Statins 64 (20.8) 244 (79.2) 6.47 <0.001*
Drugs for asthma and chronic obstructive lung disease 25 (8.0) 287 (92.0) 8.00 0.500
Osteoporosis drugs 4 (1.3) 304 (98.7) 1.14 0.466
Opioids 21 (6.8) 287 (93.2) 6.50 0.443
Anti-depressants 29 (9.4) 279 (90.6) 6.94 0.060
Antipsychotics 7 (2.0) 301 (98.0) 2.00 0.420
Antiepileptics 10 (3.3) 298 (96.8) 1.84 0.061
Benzodiazepines 12 (3.9) 396 (96.2) 8.69 <0.001*
Warfarin 3 (1.0) 309 (99.0) 1.16 0.520
Drugs for benign prostate hypertrophy (males only) 1 (0.8) 125 (99.2) 1.82 0.330
Reflux drugs 29 (9.4) 279 (90.6) 7.56 0.132
Laxatives 8 (2.6) 300 (97.4) 1.60 0.124
Tranexamic acid 1 (0.3) 307 (99.7) 0.30 0.604
Incontinence drugs 4 (1.3) 304 (98.7) 0.55 0.092
Parkinson drugs 4 (1.3) 304 (98.7) 0.60 0.116
Drug treatment of metabolic syndrome 10 (3.2) 302 (96.8) 2.05 0.105
Diuretics 56 (18.2) 252 (81.8) 9.04 <0.001*
Nasal steroids 8 (2.6) 300 (97.4) 3.80 0.170
Female hormones (females only) 30 (16.5) 152 (83.5) 25.13 0.003*
Comorbidities
Diabetes 36 (11.5) 276 (88.5) 4.8§ <0.001*
Hypertension 132 (42.3) 180 (57.7) 17.2§ <0.001*
Ischemic heart disease 24 (7.8) 285 (92.2) 3.8§ 0.001*
Heart failure 12 (3.9) 294 (96.1) 1.1¶ <0.001*
(Continued)
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AE patients. Angioedema associated deaths are rare, but has
been described as increasing due to the increased use of
ACEi.43 Selection bias could play a role in the number of
acute airway managements, since patients with head and
neck AE are more likely to be referred to a tertiary care
hospital, as it is potentially lethal. Patients with minor AE
incidents in other locations are probably handled in general
practice and thus never present in the hospital sector. Twelve
patients presented with AE in the abdomen, but none of these
patients presented with abdomen as the only afflicted area.
This supports the assumption that single-area intra-
abdominal AE is underreported due to the difficulty in
diagnostics.17,44
Hospitalization and ER visit were observed in 43.2%
and 40.3% of cases, respectively, establishing how AE is
a patient group that requires acute resources in the medical
care system. A study revealed increased annual number of
admissions and costs due to AE during the period of 1998
to 2005.45
Prior studies reporting a great variation in admission
rates of 25–84% for all AE types.39 These data do not
indicate a dissimilarity in hospitalizations of primary AE
compared to general AE. Older age, and ACEi-induced
AE were reported as parameters significantly associated
with admission.
Anti-allergic standard treatment (antihistamines, corti-
costeroids, adrenaline) was most frequently administered
to patients in this cohort, despite the fact that these drugs
are ineffective for patients with non-histaminergic AE.17
Treatment of AE is based on pathophysiology, but this is
rarely possible in the acute setting to determine the under-
lying mediator of AE. Many of the patients in this study
were reported with good effect of antihistamines and cor-
ticosteroids even though none showed clinical signs of
urticaria. The plausible explanation is a combination of
factors: some of these patients have histaminergic AE and
respond to treatment, and for AE the swelling is self-
limiting, and this can lead to the wrong conclusion of
a response to anti-allergic therapy.
Today the first-line treatment of acute AE is antihista-
mines, corticosteroids and if necessary, adrenalin. This
favours the larger group of patients with histaminergic AE.
Crochet et al revealed a 45-fold higher mortality risk for non-
histaminergic compared to histaminergic patients.18 This
could be due to the first-line treatment targeting histaminer-
gic- and not non-histaminergic patients. In this study, 24
patients were treated with other drugs than the anti-allergic
drugs. Six ACEi-induced AE patients, three idiopathic AE,
and two AE caused by physical stimuli were treated off the
label with tranexamic acid or icatibant. One patient with AE
caused by physical stimuli was treated with attenuated andro-
gens and C1-INH concentrate. The efficacywas unclear from
the medical record. C1-INH concentrate, icatibant, attenu-
ated androgens and tranexamic acid approved for C1-INH-
HAE, has shown promising results for other patients with
non-histaminergic AE.2,41,46,48 Mansi et al found a reduction
in symptoms and severity in patients with idiopathic non-
histaminergic AE treated with tranexamic acid, especially in
long-term prophylaxis for patients with recurrent severe AE
attacks.2 Baş et al found a significant reduction in time to
complete resolution in the acute phase for ACEi-induced AE
patients treated with icatibant compared to standard therapy
(from 27.1- to 8.0 hours).46 However, this was not confirmed
in subsequent studies.49,50 Fresh frozen plasma has pre-
viously been used for patients with C1-INH-HAE, but in
the western world, it is rarely used due to more effective
medication being available.7 Greve et al found a positive
effect of C1-INH concentrate for ACEi-induced AE com-
pared to a control group and an ongoing randomized doubled
blinded clinical trial is currently investigating the same.51,52
Our study revealed a significantly higher prevalence of
comorbidities in the cohort compared to the background
population. Comorbidities such as diabetes, hypertension,
asthma, ischaemic heart disease, heart failure and allergies
were also significantly associated with being admitted to
Table 5 (Continued).
Daily Drug Intake Yes, n (%) No, n (%) Background Population % p-value, Binomial Test
Allergy 93 (30.5) 212 (69.5) 19.5§ <0.001*
Drug allergy (not ACEi) 47 (15.3)
Asthma 31 (10.0) 280 (90.0) 7.6§ 0.075
Notes: Daily drug intake for 308 patients, referred between 1999–2014 compared to the background population. §Data from Medstat.dk,24 ¶Data from Christensen et al.25
n = number of patients. *Statistically significant result.
Dovepress Pall et al
Journal of Asthma and Allergy 2020:13 submit your manuscript | www.dovepress.com
DovePress
233
 
Jo
ur
na
l o
f A
st
hm
a 
an
d 
Al
le
rg
y 
do
wn
lo
ad
ed
 fr
om
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
13
0.
22
6.
23
0.
27
 o
n 
07
-O
ct
-2
02
0
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
a hospital due to AE. ACEi-induced AE and older age
were also significantly associated with being admitted.
Many patients receive ACEi due to the associated
comorbidities.
The main limitation of the study is the retrospective
design and the differences in evaluations by clinicians.
One hundred and thirty-two (17%) patients were excluded
due to insufficient data. The percentage might influence
the scientific findings. The study has no control group, and
comparison to the background population did not adjust
for age and sex due to insufficient data.
Conclusion
In this study, more than one-third of patients had histami-
nergic AE. This establishes how histaminergic AE does
often occur without hives. Our study found idiopathic AE
as the most frequent type of primary AE. However, little is
known about the pathophysiology of this heterogenic
group of patients. Forty percent of patients had drug-
induced AE, with ACEi being the most frequent causative
agent. Drugs labelled for HAE are sparsely used off-label
in selected cases in the clinical setting. AE of the head and
neck area, which can become life-threatening, occurred in
the majority of patients. Six of seven patients needing
acute airway management had ACEi-induced AE as an
underlying factor. Female sex and smoking were con-
firmed to be risk factors of primary AE. Patients with
ACEi as a causative agent have a significant increased
risk of admission compared to other types of primary AE.
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